BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront

A new era for UK-Japanese scientific research relations

Japan’s healthcare needs. Japan’s healthcare economy has evolved immensely since WWII. ... Historically, Japan has struggled to recruit patients and conduct trials within its domestic population.

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

The company said its would leverage its presence in Japan and other Asia-Pacific markets to maximise the potential of bemarituzumab in the gastric cancer market.

Richest countries are on course to purchase one billion excess COVID-19 vaccines, new analysis finds

Using this approach, the analysis found that five countries – Australia, Canada, Japan, the UK and the US – plus the European Union, that is made up of 27 member states, could share

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]